Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.

BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time to buy.

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could expand BMRN's market in 2025.

BioMarin BMRN has announced positive results from the phase III PEGASUS study evaluating Palynziq (pegvaliase) in adolescents aged 12-17 years with phenylketonuria (PKU). The study achieved its ...

San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

SAN RAFAEL, CA, USA I April 2, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...

April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ (pegvaliase-pqpz) met its primary efficacy ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company with a market capitalization of $12.96 billion and impressive gross margins of nearly 80%, announced on Monday that its Phase 3 ...

Palynziq significantly lowered blood Phe levels in adolescents vs. diet alone. BioMarin will submit data for label expansion to health authorities this year. The ‘Trade of the Day’ is now live. Get a ...